Finance

Beta
Lists
RAPP:NASDAQ
Rapport Therapeutics Inc
$41.67
+3.17%
(+1.28) 1D
$41.67
0.00% (0.00)
After hours
Closed: Jun 30, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RAPP...
Open
$40.40
High
$43.76
Low
$40.00
Mkt. cap
1.99B
Avg. vol.
357.32K
Volume
110.00
52-wk high
$43.76
52-wk low
$11.05
EPS
-$2.60
Shares outstanding
47.83M
No. of employees
84
Open
$40.40
High
$43.76
Low
$40.00
Mkt. cap
1.99B
Avg. vol.
357.32K
Volume
110.00
52-wk high
$43.76
52-wk low
$11.05
EPS
-$2.60
Shares outstanding
47.83M
No. of employees
84
News stories
From sources across the web
About Rapport Therapeutics Inc
CEO-
Employees84
Founded2022
HeadquartersBoston, Massachusetts, United States
SectorPharmaceutical industry
Websiterapportrx.com
Analyst ratings
Based on 9 analysts giving stock ratings to RAPP in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for RAPP in the last 3 months.
Highest
Current $41.67
$66.00 (+58.39%)
Average
$55.25 (+32.59%)
Lowest
$46.00 (+10.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Marc Goodman
Leerink Partners
Buy
Initiated
$52.00
+24.8%
06/24/2026
Kambiz Yazdi
BTIG
Buy
Maintained
$65.00
+56%
06/01/2026
Danielle Brill
Truist Financial
Buy
Maintained
$56.00
+34.4%
05/19/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$56.00
+34.4%
05/12/2026
Justin Walsh
JonesTrading
Buy
Reiterated
$50.00
+20%
05/07/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
05/07/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
$46.00
+10.4%
04/22/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$51.00
+22.4%
04/21/2026
Unknown Analyst
Raymond James
Buy
Initiated
$66.00
+58.4%
04/09/2026
Tiago Fauth
Raymond James
Buy
Initiated
$66.00
+58.4%
04/09/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
03/17/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$40.00
-4%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
20.00M
Cost of goods sold
-
-
-
32.72M
Cost of revenue
-
-
-
32.72M
Research and development expenses
22.68M
22.28M
30.26M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.82M
7.71M
8.25M
11.50M
Operating expense
29.50M
29.99M
38.51M
11.50M
Total operating expenses
29.50M
29.99M
38.51M
44.22M
Operating income
-29.50M
-29.99M
-38.51M
-24.22M
Other non operating income
-
-
-
-
EBT including unusual items
-26.73M
-26.92M
-33.76M
-19.86M
EBT excluding unusual items
-26.73M
-26.92M
-33.76M
-19.86M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-26.73M
-26.92M
-33.76M
-19.86M
Net profit margin
-
-
-
-99.28%
Earnings per share
-0.75
-0.71
-0.72
-0.42
Interest and investment income
2.76M
3.06M
4.75M
4.36M
Interest expense
-
-
-
-
Net interest expenses
2.76M
3.06M
4.75M
4.36M
Depreciation and amortization charges
-
-
-
-
EBITDA
-29.24M
-29.73M
-38.24M
-23.99M
Gain or loss from assets sale
-
-
-
153.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer